Should a woman with recurrent vulvovaginal itching, dryness, and fissuring that flare after menstruation and after antibiotic courses be treated now, and what features distinguish this condition from lichen sclerosus?

Yes, Treatment Should Continue Now

Given the recurrent pattern of vulvovaginal symptoms following menstruation and antibiotic use, with rapid response to antifungal therapy (Canesten), this presentation is most consistent with recurrent vulvovaginal candidiasis (RVVC) requiring ongoing treatment, not lichen sclerosus.

Why This Is Not Lichen Sclerosus

The clinical pattern clearly distinguishes this from lichen sclerosus through several key features:

Timing and Triggers

• Hormonal cyclicity: Symptoms appearing specifically around menstruation suggest candidiasis, which is influenced by hormonal fluctuations 1
• Antibiotic-triggered episodes: The two antibiotic courses preceded symptom onset, a classic trigger for candidal overgrowth 1
• Rapid symptom resolution: Symptoms disappeared within 1-2 days of antifungal treatment—lichen sclerosus would not respond this quickly to antifungal therapy

Clinical Presentation Differences

Lichen sclerosus presents with 2:

• Porcelain-white papules and plaques with areas of ecchymosis
• Persistent symptoms that worsen at night and disturb sleep
• Progressive anatomic changes: clitoral hood fusion, labial regression, introital stenosis
• Depigmentation and atrophy as major features 3
• Chronic, unremitting course requiring long-term topical corticosteroids 4

Your presentation shows:

• Cyclical symptoms that completely resolve between episodes
• Rapid antifungal response (symptoms milder day 1, gone day 2)
• Fissures appearing after inflammation resolves—these are healing fissures from acute candidal inflammation, not the chronic fissuring of lichen sclerosus 2
• Progressively milder episodes with treatment, not the chronic progressive course of lichen sclerosus

Histopathologic Distinctions

If biopsy were performed 3:

• Lichen sclerosus shows: diffuse dermal sclerosis (76.8%), interstitial inflammation pattern (81.4%), homogenized dermis
• Candidiasis shows: acute inflammation without dermal sclerosis or the characteristic architectural changes of lichen sclerosus

Treatment Recommendation

You meet criteria for RVVC (≥3 episodes in 12 months) and require suppressive maintenance therapy 1:

Immediate Management

• Confirm diagnosis: Obtain vaginal culture/microscopy during next symptomatic episode to identify Candida species
• Consider pH testing—vaginal pH affects antifungal efficacy significantly 1

Maintenance Protocol

Following CDC 2021 guidelines 1:

1. Induction phase: Topical azole (like Canesten/clotrimazole) for 7-14 days during next episode
2. Maintenance phase: Oral fluconazole 150mg weekly for 6 months, OR topical azole therapy weekly

Quality of life consideration: Maintenance fluconazole improves quality of life in 96% of women with RVVC 1, though 63% may have recurrence after stopping maintenance therapy 1

Important Caveats

• pH matters: Antifungal MICs are significantly higher at vaginal pH 4 versus laboratory pH 7, particularly for terconazole against C. glabrata (388-fold difference) 1
• Species identification: If standard azole therapy fails, consider non-albicans Candida species with different susceptibility patterns
• Antibiotic stewardship: Future antibiotic courses should be accompanied by prophylactic antifungal therapy

When to Reconsider Diagnosis

Biopsy would be indicated if 2:

• Symptoms persist despite appropriate antifungal therapy
• White plaques develop that don't resolve
• Progressive scarring or anatomic changes occur
• Symptoms become constant rather than cyclical

The decreasing severity of episodes with antifungal treatment confirms you're on the correct diagnostic and therapeutic path—continue treatment rather than stopping now.